



Small, but heading for a big time

2012 Revenues

Paris, France, January 25, 2013 – NANOBIOTIX (Euronext : NANO – ISIN: FR0011341205), a French company pioneer in nanomedicine developing NanoXray, a revolutionary therapeutic approach to local cancer treatment, today announces its revenues for the 4th quarter and full year 2012.

Quarterly revenues and for 2012

<i>In €</i>	Q1 2012	Q2 2012	Q3 2012	Q4 2012	2012*
Licenses	0	0	27,744	46,409	74,153
Services	0	0	0	0	0
Revenues	0	0	27,744	46,409	74,153

** in 2011 the Company recorded no revenue*

In the 4th quarter of 2012, the Company's revenues came to €46,409, which corresponds to the pro rata share, over such quarter, of the €810,640 upfront payment received within the framework of a license contract with PharmaEngine for the Asia-Pacific region. The revenue is comparable to the one recorded over the 3rd quarter 2012, totaling €74,153 over the year. This amount is in line with the Company's strategic plan; its business model being based on the commercialization of NBTXR3, which implies to first focus on the product's development and clinical approval by the relevant authorities.

Public funding for research expenditures, which comprises research tax credit, is not included in the revenues but is part of the Company's operating revenues, released with half and full year results.

As a reminder, since the Company's IPO on the regulated market of NYSE Euronext in Paris, several major events have marked the end of the year:

- November 2012: released of positive results for the first group of patients regarding the safety of NBTXR3, currently being tested in a phase I study at the Institut Gustave Roussy, France, on patients with advanced Soft Tissue Sarcoma. The treatment for this indication is sensitive due to the difficult access to the tumor, which specificity has been intentionally selected by NANOBIOTIX in order to demonstrate the innocuity of the product through a difficult case. This initial step is "derisking" NANOBIOTIX approach and gives the Company confidence to expand its clinical development to different indications.
- December 2012: Laurent Levy elected Vice-Chairman of the European Technology Platform on Nanomedicine (ETPN), representing European SMEs in the Executive Board. This nomination confirms NANOBIOTIX' objective to stand as a reference player on its market, while promoting its experience to the industry players in order to help structuring and developing the nanomedicine field in Europe.



Next Financial press release: annual results, April 29, 2013

About NBTXR3

NBTXR3, the lead compound of NANOBIOTIX's NanoXray product pipeline, is a nanoparticle formulation of hafnium oxide crystals for the local treatment of tumors to enhance the efficacy of radiotherapy. NBTXR3 has been classified in the EU as class III medical device and is currently being tested in a European Phase I trial to establish feasibility and safety of NBTXR3 in patients with advanced soft tissue sarcoma. Further clinical trials are in preparation in Europe, in Asia-Pacific (through the PharmaEngine partnership) and in the United States, where NBTXR3 is classified as a drug by the FDA.

Additional information on the Company's NBTXR3 Phase I trial may be found at www.clinicaltrials.gov / registration number RCB 2011-A00342-39

About NANOBIOTIX: www.NANOBIOTIX.com/fr

NANOBIOTIX, pioneer and leader in nanomedicine, has developed a revolutionary concept dedicated to the local treatment of cancer. NANOBIOTIX is focused on the development of NanoXray, a pipeline of patented products, which are based on the physical mechanism of action of the nanoparticles interacting with X-rays and maximizing radiation effect into tumor cells. NanoXray products enhance the efficacy of the radiotherapy in the tumor without increasing healthy tissues damages. NanoXray products can be used with existing standard radiation equipments available in almost every hospital world-wide.

NANOBIOTIX is a spin-off of the State University of New York (SUNY) at Buffalo that was incorporated in 2003 and has been primarily funded by leading European venture capital firms. The company has more than 30 employees and is based in Paris, France. NANOBIOTIX's objective is to enhance its leading position in the nanomedicine field on the main oncology markets. Its pipeline of universal products enable to target the major indications of cancers (breast cancer, prostate cancer, lung cancer...), leading to a potential market of several billion dollars. Thanks to the physical based mechanism of action of its nanoparticles, NANOBIOTIX deploys a unique business model with much lower risk than classic drug development, enabling a faster and less expensive time to market. NANOBIOTIX is listed on the regulated market of NYSE Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO:FP).



Contacts

NANOBIOTIX

Laurent Levy

CEO and Co-founder

Tel: +33 (0)1 40 26 04 70

contact@NANOBIOTIX.com

NewCap.

Financial communication and
Investor relations

Louis-Victor Delouvrier /

Emmanuel Huynh

Tel: +33 (0)1 44 71 98 53

lvdelouvrier@newcap.fr

Yucatan

Press Relations

Annie-Florence Loyer /

Nadège Le Lezec

Tel: +33 (0)1 53 63 27 27

afloyer@yucatan.tm.fr

